Reversing anti–factor Xa agents and the unmet needs in trauma patients

Beverley J. Hunt; Matthew D. Neal; Jakob Stensballe

doi:10.1182/blood-2018-06-850396

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Beverley J. Hunt^*, Matthew D. Neal, Jakob Stensballe

^*Corresponding author for this work

Comprehensive Cancer Centre

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Andexanet alfa, a reversing agent for anticoagulants that inhibit factor Xa, has recently been licensed in the United States. We discuss the impact of this licensure on current practice and review in detail the problems of a neglected and growing clinical area: reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.

Original language	English
Pages (from-to)	2441-2445
Number of pages	5
Journal	Blood
Volume	132
Issue number	23
Early online date	11 Oct 2018
DOIs	https://doi.org/10.1182/blood-2018-06-850396
Publication status	E-pub ahead of print - 11 Oct 2018

Access to Document

10.1182/blood-2018-06-850396

Cite this

@article{04040453b8a64302bc05adc5c0f86ac9,

title = "Reversing anti–factor Xa agents and the unmet needs in trauma patients",

abstract = "Andexanet alfa, a reversing agent for anticoagulants that inhibit factor Xa, has recently been licensed in the United States. We discuss the impact of this licensure on current practice and review in detail the problems of a neglected and growing clinical area: reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.",

author = "Hunt, {Beverley J.} and Neal, {Matthew D.} and Jakob Stensballe",

year = "2018",

month = oct,

day = "11",

doi = "10.1182/blood-2018-06-850396",

language = "English",

volume = "132",

pages = "2441--2445",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - Reversing anti–factor Xa agents and the unmet needs in trauma patients

AU - Hunt, Beverley J.

AU - Neal, Matthew D.

AU - Stensballe, Jakob

PY - 2018/10/11

Y1 - 2018/10/11

N2 - Andexanet alfa, a reversing agent for anticoagulants that inhibit factor Xa, has recently been licensed in the United States. We discuss the impact of this licensure on current practice and review in detail the problems of a neglected and growing clinical area: reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.

AB - Andexanet alfa, a reversing agent for anticoagulants that inhibit factor Xa, has recently been licensed in the United States. We discuss the impact of this licensure on current practice and review in detail the problems of a neglected and growing clinical area: reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.

UR - http://www.scopus.com/inward/record.url?scp=85057724746&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-06-850396

DO - 10.1182/blood-2018-06-850396

M3 - Article

AN - SCOPUS:85057724746

SN - 0006-4971

VL - 132

SP - 2441

EP - 2445

JO - Blood

JF - Blood

IS - 23

ER -

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this